
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
At AMCP 2019, Cate Lockhart, MS, PharmD, PhD, executive director at Biologics and Biosimilars Collective Intelligence Consortium, discusses accelerating the uptake of biosimilars in the U.S. market.






